Nurix Therapeutics, Inc.
NRIX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001549595
In the last 90 days, Nurix Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 211 institutions reported holding it in 13F filings for Q2 2026, worth $2.84B in total; ARK Invest is the only superinvestor holding it.
Q3 2023 vs. Q2 2023
How the institutions holding Nurix Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 126 | 1 | 129 | +4 |
| Shares | 43.6M | 930.9K | 44.8M | +2.11M (+5.0%) |
| Value | $435.7M | $9.30M | $352.5M | −$73.9M (−17.3%) |
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (14)
Institutions that held Nurix Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Pictet Asset Management Holding SA | 897,809 | $7.06M | 0.01% |
| Soleus Capital Management, L.P. | 814,000 | $6.40M | 0.64% |
| ArrowMark Colorado Holdings LLC | 314,762 | $2.47M | 0.03% |
| Marshall Wace, LLP | 127,509 | $1.00M | 0.00% |
| Ameriprise Financial Inc | 60,318 | $474.1K | 0.00% |
| Renaissance Technologies LLC | 26,800 | $211.0K | 0.00% |
| Balyasny Asset Management LLC | 26,275 | $206.5K | 0.00% |
| Man Group plc | – | $188.5K | 0.00% |
| XTX Topco Ltd | 21,937 | $172.4K | 0.03% |
| BBR Partners, LLC | 20,988 | $165.0K | 0.02% |
| SG Americas Securities, LLC | 20,639 | $162.0K | 0.00% |
| Aquatic Capital Management LLC | 1,800 | $14.0K | 0.00% |
| Point72 Middle East FZE | 651 | $5.12K | 0.00% |
| Comerica Bank | 259 | $2.04K | 0.00% |
Sold out (10)
Institutions that held Nurix Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Harvard Management Co Inc | 314,762 | $3.14M |
| Nomura Holdings Inc | 130,040 | $1.30M |
| Jefferies Financial Group Inc. | 62,000 | $619.4K |
| HRT Financial LP | 28,432 | $284.0K |
| Nebula Research & Development LLC | 16,025 | $160.1K |
| Innovis Asset Management LLC | 15,648 | $156.3K |
| Delphia (USA) Inc. | 14,239 | $142.2K |
| Tudor Investment Corp Et Al | 12,991 | $129.8K |
| Graham Capital Management, L.P. | 10,783 | $107.7K |
| CWM, LLC | 35 | $0 |
Not filed for Q3 2023 yet (1)
Institutions that held Nurix Therapeutics, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Pictet Asset Management SA | 930,914 | $9.30M |